Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.36 |
| ▸ | RXRA | P19793 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30580207 | 0.98 | CSNK2A1 (0.42) | CSNK2A1LOXL2KCNH2CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL25370524 | 0.98 | CSNK2A1 (0.42) | CSNK2A1LOXL2KCNH2CYP4F2CYP4A11 | |
| SCHEMBL13593481 | 0.86 | CSNK2A1 (0.39) | CSNK2A1LOXL2CYP4F2CYP4A11 | |
| SCHEMBL2440368 | 0.85 | CSNK2A1 (0.45) | CSNK2A1LOXL2 | |
| SCHEMBL7909260 | 0.85 | CSNK2A1 (0.47) | CSNK2A1LOXL2 | |
| Hydrochloric Acid SCHEMBL2282287 | 0.83 | CSNK2A1 (0.49) | CSNK2A1LOXL2 | |
| SCHEMBL22981790 | 0.81 | KCNH2 (0.39) | KCNH2CYP4F2CYP4A11GRIN2BGRIN1 | |
| SCHEMBL8171104 | 0.81 | KCNH2 (0.41) | KCNH2CYP4F2CYP4A11GRIN2BGRIN1 | |
| SCHEMBL22981677 | 0.81 | CYP4F2 (0.56) | KCNH2CYP4F2CYP4A11GRIN2BGRIN1 | |
| SCHEMBL8226028 | 0.81 | KCNH2 (0.39) | KCNH2CYP4F2CYP4A11GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | CSNK2A1 3624/4885LOXL2 969/4885KCNH2 4495/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | CSNK2A1 4586/4885LOXL2 1949/4885KCNH2 4492/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CSNK2A1 4586/4885LOXL2 1949/4885KCNH2 4492/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CSNK2A1 4586/4885LOXL2 1949/4885KCNH2 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.